Trial Outcomes & Findings for A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (NCT NCT02020889)

NCT ID: NCT02020889

Last Updated: 2018-01-31

Results Overview

Total accrued duration of remission is the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=4 mg/day over the 52 week study treatment period was reported. The accrued duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. Intent-to-Treat (ITT) Population was used for the analysis and was defined as all participants who were randomized and received at least one dose of trial medication. Randomized participants were assumed to have received study treatment unless definitive evidence to the contrary exists. The odds ratio for treatment difference and associated probability (p)-value and 95 percent confidence interval (CI) were calculated.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

136 participants

Primary outcome timeframe

Up to Week 52

Results posted on

2018-01-31

Participant Flow

Eligible participants at screening and run-in visit, entered a 52 week study treatment phase followed by 8-week follow-up phase. The total duration for the study participation was approximately 64 weeks.

A total of 151 participants with a history of relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) were screened, out of which 4 were screen failures and 11 were run-in failures. 136 participants completed run-in period and received Mepolizumab 300 milligram (mg) or placebo in a randomized manner in the treatment phase.

Participant milestones

Participant milestones
Measure	Placebo Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Overall Study STARTED	68	68
Overall Study COMPLETED	61	65
Overall Study NOT COMPLETED	7	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Placebo Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Overall Study Adverse Event	0	1
Overall Study Lack of Efficacy	1	0
Overall Study Lost to Follow-up	1	0
Overall Study Physician Decision	2	0
Overall Study Withdrawal by Subject	3	2

Baseline Characteristics

A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.	Total n=136 Participants Total of all reporting groups
Age, Continuous	48.2 Years STANDARD_DEVIATION 14.32 • n=5 Participants	48.7 Years STANDARD_DEVIATION 12.39 • n=7 Participants	48.5 Years STANDARD_DEVIATION 13.34 • n=5 Participants
Sex: Female, Male Female	38 Participants n=5 Participants	42 Participants n=7 Participants	80 Participants n=5 Participants
Sex: Female, Male Male	30 Participants n=5 Participants	26 Participants n=7 Participants	56 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · American Indian or Alaskan Native	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · Asian - Japanese Heritage	3 Participants n=5 Participants	3 Participants n=7 Participants	6 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · Asian - South East Asian Heritage	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · White - Arabic/North African Heritage	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · White - White/Caucasian/European Heritage	61 Participants n=5 Participants	62 Participants n=7 Participants	123 Participants n=5 Participants
Race/Ethnicity, Customized Race customized · Mixed Race	2 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants

PRIMARY outcome

Timeframe: Up to Week 52

Population: ITT Population

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants in Each Category of Accrued Duration of Remission Zero	55 Participants	32 Participants
Number of Participants in Each Category of Accrued Duration of Remission >0 to <12 weeks	8 Participants	8 Participants
Number of Participants in Each Category of Accrued Duration of Remission 12 to <24 weeks	3 Participants	9 Participants
Number of Participants in Each Category of Accrued Duration of Remission 24 to <36 weeks	0 Participants	10 Participants
Number of Participants in Each Category of Accrued Duration of Remission >=36 weeks	2 Participants	9 Participants

PRIMARY outcome

Timeframe: Week 36 and Week 48

Population: ITT Population

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=4 mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants Who Are in Remission at 36 and 48 Weeks	2 Participants	22 Participants

SECONDARY outcome

Timeframe: Up to Week 52

Population: ITT Population

EGPA relapse was defined as worsening or persistence of active disease since the last visit characterized by active vasculitis or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire-6 (ACQ-6) score or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting: i) an increased dose of OCS therapy (or other systemic corticosteroid therapy) to \>4 mg/day prednisolone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Participants who completed study, or withdrawn prematurely from the study without experiencing the event were censored. The number of participants with at least one EGPA relapse during the planned study treatment period are presented.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Time to First EGPA Relapse	56 Participants	38 Participants

SECONDARY outcome

Timeframe: Week 48 and Week52

Population: ITT Population

The number of participants with an average daily prednisolone/prednisone dose during the last 4 weeks of the Study Treatment Period (48 through 52) was calculated. The average dose was categorized into zero, \>0 to \<=4.0mg, \>4.0 to \<=7.5mg and \>7.5mg. The statistical analysis was performed using a proportional odds regression model with Baseline covariates of treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region and the comparison between treatment groups was presented as an odds ratio, p-value and 95 percent CI.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period. Zero	2 Participants	12 Participants
Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period. >0 to <=4.0mg	3 Participants	18 Participants
Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period. >4.0 to <=7.5mg	18 Participants	10 Participants
Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period. >7.5mg	45 Participants	28 Participants

SECONDARY outcome

Timeframe: Up to Week 52

Population: ITT Population

The number of participants who achieved remission (i.e., BVAS=0 and prednisolone/prednisone\<=4 mg/day) within the first 24 weeks and remain in remission for the remainder of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	1 Participants	13 Participants

SECONDARY outcome

Timeframe: Up to Week 52

Population: ITT Population

Total accrued duration of remission, i.e., the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose \<=7.5mg/day over the 52 week study treatment period was reported. BVAS is a validated, clinician-completed tool used for the comprehensive multisystem clinical assessment of disease activity in systemic vasculitis. The duration was categorized into zero, \>0 to \<12 weeks, 12 to \<24 weeks, 24 to \<36 weeks and \>=36 weeks. Statistical analysis was performed on ITT Population and was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants in Each Category of Accrued Duration of Remission Zero	36 Participants	15 Participants
Number of Participants in Each Category of Accrued Duration of Remission >0 to <12 weeks	19 Participants	15 Participants
Number of Participants in Each Category of Accrued Duration of Remission 12 to <24 weeks	0 Participants	7 Participants
Number of Participants in Each Category of Accrued Duration of Remission 24 to <36 weeks	7 Participants	9 Participants
Number of Participants in Each Category of Accrued Duration of Remission >=36 weeks	6 Participants	22 Participants

SECONDARY outcome

Timeframe: Week 36 and Week 48

Population: ITT Population

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone \<=7.5mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants Who Are in Remission at 36 and 48 Weeks	7 Participants	28 Participants

SECONDARY outcome

Timeframe: Up to Week 52

Population: ITT Population

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period	2 Participants	16 Participants

SECONDARY outcome

Timeframe: Up to Week 52

Population: Safety Population

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs including systemic allergic and non-allergic reactions as well as local site injection-related reactions were counted throughout treatment phase and follow up phase. Systemic allergic reactions included Facial paralysis, flushing, hypersensitivity and rash pruritic. Injection related reactions were considered as systemic non-allergic reactions. Local site reactions included injection site bruising, erythema, pain and reaction. The analysis was performed on Safety Population which comprised of all participants who receive at least one dose of study treatment.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Number of Participants With Local and Systemic Adverse Events (AEs) Facial paralysis	1 Participants	0 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Flushing	0 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Hypersensitivity	0 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Rash pruritic	0 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Injection related reactions	0 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Injection site bruising	0 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Injection site erythema	1 Participants	1 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Injection site pain	1 Participants	0 Participants
Number of Participants With Local and Systemic Adverse Events (AEs) Injection site reaction	7 Participants	9 Participants

SECONDARY outcome

Timeframe: Baseline and up to Week 60

Population: Safety Population

Pulse rate was measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Outcome measures

SECONDARY outcome

Timeframe: Baseline and up to Week 60

Population: Safety Population

Body temperature was measured from Baseline throughout follow-up (till Week 60). The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. The analysis was performed on Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Body Temperature Absolute Baseline; n= 68, 68	36.52 Degree celsius Standard Deviation 0.385	36.51 Degree celsius Standard Deviation 0.462
Change From Baseline in Body Temperature Week 4; n= 68, 68	0.05 Degree celsius Standard Deviation 0.439	-0.04 Degree celsius Standard Deviation 0.411
Change From Baseline in Body Temperature Week 8; n= 67,68	-0.01 Degree celsius Standard Deviation 0.379	-0.02 Degree celsius Standard Deviation 0.425
Change From Baseline in Body Temperature Week 12; n= 66, 68	0.05 Degree celsius Standard Deviation 0.410	-0.03 Degree celsius Standard Deviation 0.447
Change From Baseline in Body Temperature Week 16; n= 64, 68	-0.01 Degree celsius Standard Deviation 0.421	-0.03 Degree celsius Standard Deviation 0.432
Change From Baseline in Body Temperature Week 20; n= 63, 68	-0.08 Degree celsius Standard Deviation 0.351	-0.13 Degree celsius Standard Deviation 0.376
Change From Baseline in Body Temperature Week 24; n= 62, 67	-0.06 Degree celsius Standard Deviation 0.449	-0.06 Degree celsius Standard Deviation 0.389
Change From Baseline in Body Temperature Week 28; n= 63, 67	-0.06 Degree celsius Standard Deviation 0.499	-0.14 Degree celsius Standard Deviation 0.411
Change From Baseline in Body Temperature Week 32; n= 62, 67	-0.09 Degree celsius Standard Deviation 0.392	-0.07 Degree celsius Standard Deviation 0.355
Change From Baseline in Body Temperature Week 36; n= 62, 67	-0.05 Degree celsius Standard Deviation 0.431	0.03 Degree celsius Standard Deviation 0.468
Change From Baseline in Body Temperature Week 40; n= 62, 66	-0.03 Degree celsius Standard Deviation 0.530	-0.13 Degree celsius Standard Deviation 0.406
Change From Baseline in Body Temperature Week 44; n= 61, 65	-0.03 Degree celsius Standard Deviation 0.550	-0.08 Degree celsius Standard Deviation 0.396
Change From Baseline in Body Temperature Week 48; n= 61, 64	-0.04 Degree celsius Standard Deviation 0.452	-0.09 Degree celsius Standard Deviation 0.414
Change From Baseline in Body Temperature Week 52; n= 60, 65	-0.04 Degree celsius Standard Deviation 0.423	-0.12 Degree celsius Standard Deviation 0.541
Change From Baseline in Body Temperature Week 56; n= 61, 63	-0.08 Degree celsius Standard Deviation 0.530	-0.00 Degree celsius Standard Deviation 0.402
Change From Baseline in Body Temperature Week 60; n= 61, 64	0.03 Degree celsius Standard Deviation 0.467	-0.02 Degree celsius Standard Deviation 0.479

SECONDARY outcome

Timeframe: Baseline and up to Week 60

Population: Safety Population

Single measurements of 12-lead electrocardiogram (ECGs) were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Mean change from Baseline in QTcF and QTcB values were measured. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Outcome measures

SECONDARY outcome

Timeframe: Baseline and up to Week 60

Population: Safety Population

Single measurements of 12-lead ECGs were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Maximum change from Baseline in QTcF and QTcB values were measured.

Outcome measures

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Maximum Change From Baseline in QTcF and QTcB Values QTcB interval	18.8 msec Standard Deviation 26.46	18.1 msec Standard Deviation 15.28
Maximum Change From Baseline in QTcF and QTcB Values QTcF interval	16.9 msec Standard Deviation 23.74	15.4 msec Standard Deviation 13.79

Adverse Events

Placebo

Serious events: 18 serious events

Other events: 61 other events

Deaths: 0 deaths

Mepolizumab 300mg

Serious events: 12 serious events

Other events: 65 other events

Deaths: 1 deaths

Serious adverse events

Other adverse events

Additional Information

GSK Response Center

GlaxoSmithKline

Phone: 866-435-7343

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Absolute Albumin; Baseline; n= 68, 68	43.4 gram per liter (g/L) Standard Deviation 2.45	43.5 gram per liter (g/L) Standard Deviation 3.01
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 4; n= 68, 68	-0.6 gram per liter (g/L) Standard Deviation 2.25	-0.1 gram per liter (g/L) Standard Deviation 2.16
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 8; n= 67, 66	-0.8 gram per liter (g/L) Standard Deviation 2.16	-0.6 gram per liter (g/L) Standard Deviation 2.72
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 12; n= 65, 68	-0.2 gram per liter (g/L) Standard Deviation 2.47	-0.4 gram per liter (g/L) Standard Deviation 2.64
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 16; n= 65, 68	-0.6 gram per liter (g/L) Standard Deviation 2.57	-0.6 gram per liter (g/L) Standard Deviation 2.54
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 20; n= 63, 68	-0.1 gram per liter (g/L) Standard Deviation 2.35	-0.2 gram per liter (g/L) Standard Deviation 2.92
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 24; n= 63, 66	0.0 gram per liter (g/L) Standard Deviation 2.80	0.1 gram per liter (g/L) Standard Deviation 2.72
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 28; n= 62, 66	-0.2 gram per liter (g/L) Standard Deviation 2.67	0.1 gram per liter (g/L) Standard Deviation 2.67
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 32; n= 61, 67	-0.4 gram per liter (g/L) Standard Deviation 2.71	-0.1 gram per liter (g/L) Standard Deviation 2.69
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 36; n= 60, 67	-0.1 gram per liter (g/L) Standard Deviation 2.58	0.3 gram per liter (g/L) Standard Deviation 3.01
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 40; n= 61, 66	-0.2 gram per liter (g/L) Standard Deviation 2.98	0.2 gram per liter (g/L) Standard Deviation 2.82
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 44; n= 61, 66	0.3 gram per liter (g/L) Standard Deviation 2.95	-0.3 gram per liter (g/L) Standard Deviation 2.87
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 48; n= 61, 64	-0.4 gram per liter (g/L) Standard Deviation 2.74	-0.3 gram per liter (g/L) Standard Deviation 2.77
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 52; n= 60, 65	-0.5 gram per liter (g/L) Standard Deviation 2.45	-0.3 gram per liter (g/L) Standard Deviation 3.10
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 56; n= 61, 63	-0.7 gram per liter (g/L) Standard Deviation 2.84	-0.5 gram per liter (g/L) Standard Deviation 2.88
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Albumin; Week 60; n= 60, 65	-0.9 gram per liter (g/L) Standard Deviation 2.55	-0.7 gram per liter (g/L) Standard Deviation 3.04
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Absolute Protein; Baseline; n= 68, 68	67.7 gram per liter (g/L) Standard Deviation 4.26	67.3 gram per liter (g/L) Standard Deviation 4.46
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 4; n= 68, 68	-0.8 gram per liter (g/L) Standard Deviation 3.00	-0.5 gram per liter (g/L) Standard Deviation 3.19
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 8; n= 67, 66	-1.5 gram per liter (g/L) Standard Deviation 2.97	-0.9 gram per liter (g/L) Standard Deviation 3.60
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 12; n= 65, 68	-0.6 gram per liter (g/L) Standard Deviation 3.57	-0.6 gram per liter (g/L) Standard Deviation 3.30
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 16; n= 65, 68	-0.3 gram per liter (g/L) Standard Deviation 3.56	-0.8 gram per liter (g/L) Standard Deviation 3.93
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 20; n= 63, 68	0.0 gram per liter (g/L) Standard Deviation 3.21	0.1 gram per liter (g/L) Standard Deviation 4.28
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 24; n= 63, 66	0.2 gram per liter (g/L) Standard Deviation 3.99	0.0 gram per liter (g/L) Standard Deviation 3.96
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 28; n= 62, 66	-0.2 gram per liter (g/L) Standard Deviation 4.13	-0.1 gram per liter (g/L) Standard Deviation 3.59
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 32; n= 61, 67	-0.5 gram per liter (g/L) Standard Deviation 4.09	-0.4 gram per liter (g/L) Standard Deviation 3.91
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 36; n= 60, 67	-0.2 gram per liter (g/L) Standard Deviation 3.82	0.2 gram per liter (g/L) Standard Deviation 4.45
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 40; n= 61, 66	-0.4 gram per liter (g/L) Standard Deviation 3.48	0.1 gram per liter (g/L) Standard Deviation 3.98
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 44; n= 61, 66	0.4 gram per liter (g/L) Standard Deviation 4.43	-0.6 gram per liter (g/L) Standard Deviation 4.19
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 48; n= 61, 64	-0.5 gram per liter (g/L) Standard Deviation 3.94	-0.5 gram per liter (g/L) Standard Deviation 4.29
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 52; n= 60, 65	-0.3 gram per liter (g/L) Standard Deviation 3.75	-0.4 gram per liter (g/L) Standard Deviation 4.08
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; week 56; n= 61, 63	-0.1 gram per liter (g/L) Standard Deviation 4.77	-0.5 gram per liter (g/L) Standard Deviation 4.21
Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels Protein; Week 60; n= 60, 65	-0.4 gram per liter (g/L) Standard Deviation 5.88	-0.7 gram per liter (g/L) Standard Deviation 4.17

Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 52; n= 60, 65	0.1 micromole per liter (µmol/L) Standard Deviation 1.05	0.2 micromole per liter (µmol/L) Standard Deviation 1.06
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 56; n= 61, 63	0.1 micromole per liter (µmol/L) Standard Deviation 1.08	0.1 micromole per liter (µmol/L) Standard Deviation 1.06
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Absolute Total bilirubin; Baseline; n= 68, 68	9.8 micromole per liter (µmol/L) Standard Deviation 6.14	8.8 micromole per liter (µmol/L) Standard Deviation 4.10
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; week 4; n= 68, 68	-0.9 micromole per liter (µmol/L) Standard Deviation 4.02	0.1 micromole per liter (µmol/L) Standard Deviation 3.48
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 8; n= 67, 66	-1.2 micromole per liter (µmol/L) Standard Deviation 4.38	0.0 micromole per liter (µmol/L) Standard Deviation 3.50
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 12; n= 65, 68	-0.3 micromole per liter (µmol/L) Standard Deviation 3.01	0.1 micromole per liter (µmol/L) Standard Deviation 3.27
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 16; n= 65, 68	-1.1 micromole per liter (µmol/L) Standard Deviation 4.15	0.0 micromole per liter (µmol/L) Standard Deviation 4.14
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 20; n= 63, 68	-0.5 micromole per liter (µmol/L) Standard Deviation 2.90	0.3 micromole per liter (µmol/L) Standard Deviation 3.57
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 24; n= 63, 66	-0.3 micromole per liter (µmol/L) Standard Deviation 3.36	0.0 micromole per liter (µmol/L) Standard Deviation 2.71
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 28; n= 62, 66	-0.8 micromole per liter (µmol/L) Standard Deviation 3.13	0.3 micromole per liter (µmol/L) Standard Deviation 4.43
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 32; n= 61, 67	-1.1 micromole per liter (µmol/L) Standard Deviation 3.07	-0.1 micromole per liter (µmol/L) Standard Deviation 3.63
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 36; n= 60, 67	-0.7 micromole per liter (µmol/L) Standard Deviation 3.39	0.1 micromole per liter (µmol/L) Standard Deviation 4.09
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 40; n= 61, 66	-0.2 micromole per liter (µmol/L) Standard Deviation 3.22	-0.3 micromole per liter (µmol/L) Standard Deviation 3.78
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 44; n= 61, 66	0.0 micromole per liter (µmol/L) Standard Deviation 2.50	0.1 micromole per liter (µmol/L) Standard Deviation 3.64
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 48; n= 61, 64	-0.2 micromole per liter (µmol/L) Standard Deviation 2.59	-0.1 micromole per liter (µmol/L) Standard Deviation 3.77
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 52; n= 60, 65	-0.1 micromole per liter (µmol/L) Standard Deviation 3.41	0.7 micromole per liter (µmol/L) Standard Deviation 3.92
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 56; n= 61, 63	-0.8 micromole per liter (µmol/L) Standard Deviation 3.17	0.5 micromole per liter (µmol/L) Standard Deviation 3.24
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Total bilirubin; Week 60; n= 60, 65	-0.5 micromole per liter (µmol/L) Standard Deviation 3.21	0.0 micromole per liter (µmol/L) Standard Deviation 3.42
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Absolute Creatinine; Baseline; n= 68, 68	75.49 micromole per liter (µmol/L) Standard Deviation 12.878	73.00 micromole per liter (µmol/L) Standard Deviation 12.289
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 4; n= 68, 68	0.69 micromole per liter (µmol/L) Standard Deviation 7.195	2.09 micromole per liter (µmol/L) Standard Deviation 5.533
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 8; n= 67, 66	1.87 micromole per liter (µmol/L) Standard Deviation 7.505	1.15 micromole per liter (µmol/L) Standard Deviation 6.737
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 12; n= 65, 68	1.50 micromole per liter (µmol/L) Standard Deviation 9.029	0.34 micromole per liter (µmol/L) Standard Deviation 7.006
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 16; n= 65, 68	1.53 micromole per liter (µmol/L) Standard Deviation 10.012	2.72 micromole per liter (µmol/L) Standard Deviation 6.702
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 20; n= 63, 68	1.73 micromole per liter (µmol/L) Standard Deviation 6.916	2.60 micromole per liter (µmol/L) Standard Deviation 7.739
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 24; n= 63, 66	0.74 micromole per liter (µmol/L) Standard Deviation 7.775	0.06 micromole per liter (µmol/L) Standard Deviation 6.538
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 28; n= 62, 66	0.96 micromole per liter (µmol/L) Standard Deviation 7.504	1.02 micromole per liter (µmol/L) Standard Deviation 7.764
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 32; n= 61, 67	1.89 micromole per liter (µmol/L) Standard Deviation 9.809	1.85 micromole per liter (µmol/L) Standard Deviation 8.589
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 36; n= 60, 67	1.42 micromole per liter (µmol/L) Standard Deviation 6.957	0.40 micromole per liter (µmol/L) Standard Deviation 7.839
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 40; n= 61, 66	1.16 micromole per liter (µmol/L) Standard Deviation 8.253	0.34 micromole per liter (µmol/L) Standard Deviation 8.119
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 44; n= 61, 66	2.14 micromole per liter (µmol/L) Standard Deviation 8.991	0.04 micromole per liter (µmol/L) Standard Deviation 9.070
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 48; n= 61, 64	1.53 micromole per liter (µmol/L) Standard Deviation 7.972	-2.25 micromole per liter (µmol/L) Standard Deviation 7.398
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 52; n= 60, 65	0.52 micromole per liter (µmol/L) Standard Deviation 7.719	-1.35 micromole per liter (µmol/L) Standard Deviation 7.182
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 56; n= 61, 63	1.39 micromole per liter (µmol/L) Standard Deviation 7.367	-0.30 micromole per liter (µmol/L) Standard Deviation 8.695
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Creatinine; Week 60; n= 60, 65	0.34 micromole per liter (µmol/L) Standard Deviation 7.014	-1.22 micromole per liter (µmol/L) Standard Deviation 10.896
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Absolute Direct bilirubin; Baseline; n= 68, 68	2.1 micromole per liter (µmol/L) Standard Deviation 1.33	1.9 micromole per liter (µmol/L) Standard Deviation 0.98
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 4; n= 68, 68	0.0 micromole per liter (µmol/L) Standard Deviation 1.06	0.0 micromole per liter (µmol/L) Standard Deviation 0.84
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 8; n= 67, 66	0.0 micromole per liter (µmol/L) Standard Deviation 1.01	0.1 micromole per liter (µmol/L) Standard Deviation 0.96
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 12; n= 65, 68	0.0 micromole per liter (µmol/L) Standard Deviation 0.97	0.0 micromole per liter (µmol/L) Standard Deviation 1.04
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 16; n= 65, 68	-0.2 micromole per liter (µmol/L) Standard Deviation 0.96	-0.1 micromole per liter (µmol/L) Standard Deviation 1.20
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 20; n= 63, 68	0.0 micromole per liter (µmol/L) Standard Deviation 0.86	0.1 micromole per liter (µmol/L) Standard Deviation 1.03
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 24; n= 63, 66	0.1 micromole per liter (µmol/L) Standard Deviation 0.90	0.0 micromole per liter (µmol/L) Standard Deviation 0.88
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 28; n= 62, 66	-0.1 micromole per liter (µmol/L) Standard Deviation 1.20	0.2 micromole per liter (µmol/L) Standard Deviation 1.15
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 32; n= 61, 67	-0.2 micromole per liter (µmol/L) Standard Deviation 0.99	0.1 micromole per liter (µmol/L) Standard Deviation 0.99
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 36; n= 60, 67	-0.1 micromole per liter (µmol/L) Standard Deviation 1.11	0.1 micromole per liter (µmol/L) Standard Deviation 1.17
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 40; n= 61, 66	0.0 micromole per liter (µmol/L) Standard Deviation 1.11	0.0 micromole per liter (µmol/L) Standard Deviation 0.94
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 44; n= 61, 66	0.1 micromole per liter (µmol/L) Standard Deviation 0.93	0.0 micromole per liter (µmol/L) Standard Deviation 1.12
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 48; n= 61, 64	0.1 micromole per liter (µmol/L) Standard Deviation 0.99	0.0 micromole per liter (µmol/L) Standard Deviation 1.17
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Direct bilirubin; Week 60; n= 60, 65	0.1 micromole per liter (µmol/L) Standard Deviation 1.10	0.1 micromole per liter (µmol/L) Standard Deviation 1.07
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Absolute Indirect bilirubin; Baseline; n= 68, 68	7.7 micromole per liter (µmol/L) Standard Deviation 5.09	6.9 micromole per liter (µmol/L) Standard Deviation 3.38
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 4; n= 68, 68	-0.8 micromole per liter (µmol/L) Standard Deviation 3.68	0.0 micromole per liter (µmol/L) Standard Deviation 3.06
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 8; n= 67, 66	-1.2 micromole per liter (µmol/L) Standard Deviation 3.86	-0.1 micromole per liter (µmol/L) Standard Deviation 2.94
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 12; n= 65, 68	-0.3 micromole per liter (µmol/L) Standard Deviation 2.61	0.1 micromole per liter (µmol/L) Standard Deviation 2.79
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 16; n= 65, 68	-0.9 micromole per liter (µmol/L) Standard Deviation 3.67	0.1 micromole per liter (µmol/L) Standard Deviation 3.37
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 20; n= 63, 68	-0.5 micromole per liter (µmol/L) Standard Deviation 2.37	0.2 micromole per liter (µmol/L) Standard Deviation 3.00
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 24; n= 63, 66	-0.4 micromole per liter (µmol/L) Standard Deviation 2.94	0.0 micromole per liter (µmol/L) Standard Deviation 2.37
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 28; n= 62, 66	-0.7 micromole per liter (µmol/L) Standard Deviation 2.60	0.1 micromole per liter (µmol/L) Standard Deviation 3.71
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 32; n= 61, 66	-0.9 micromole per liter (µmol/L) Standard Deviation 2.48	-0.2 micromole per liter (µmol/L) Standard Deviation 3.02
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 36; n= 60, 67	-0.6 micromole per liter (µmol/L) Standard Deviation 2.77	0.0 micromole per liter (µmol/L) Standard Deviation 3.30
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 40; n= 61, 66	-0.1 micromole per liter (µmol/L) Standard Deviation 2.56	-0.2 micromole per liter (µmol/L) Standard Deviation 3.16
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 44; n= 61, 66	-0.1 micromole per liter (µmol/L) Standard Deviation 2.19	0.1 micromole per liter (µmol/L) Standard Deviation 2.99
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 48; n= 61, 64	-0.3 micromole per liter (µmol/L) Standard Deviation 2.19	-0.1 micromole per liter (µmol/L) Standard Deviation 3.13
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 52; n= 60, 65	-0.2 micromole per liter (µmol/L) Standard Deviation 2.84	0.5 micromole per liter (µmol/L) Standard Deviation 3.32
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 56; n= 61, 63	-0.9 micromole per liter (µmol/L) Standard Deviation 2.72	0.4 micromole per liter (µmol/L) Standard Deviation 2.64
Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels Indirect bilirubin; Week 60; n= 60, 65	-0.6 micromole per liter (µmol/L) Standard Deviation 2.64	-0.1 micromole per liter (µmol/L) Standard Deviation 2.81

Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels Absolute SBP; Baseline; n= 68, 68	127.46 millimeter of mercury (mm of Hg) Standard Deviation 17.794	122.46 millimeter of mercury (mm of Hg) Standard Deviation 14.134
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 8; n= 67, 68	0.07 millimeter of mercury (mm of Hg) Standard Deviation 14.192	1.29 millimeter of mercury (mm of Hg) Standard Deviation 11.066
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 12; n= 66, 68	-1.12 millimeter of mercury (mm of Hg) Standard Deviation 14.380	-1.41 millimeter of mercury (mm of Hg) Standard Deviation 12.071
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 16; n= 64, 68	-0.97 millimeter of mercury (mm of Hg) Standard Deviation 16.630	-0.41 millimeter of mercury (mm of Hg) Standard Deviation 11.579
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 20; n= 63, 68	-0.97 millimeter of mercury (mm of Hg) Standard Deviation 15.028	-0.85 millimeter of mercury (mm of Hg) Standard Deviation 12.019
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 28; n= 63, 67	-0.06 millimeter of mercury (mm of Hg) Standard Deviation 14.337	-0.15 millimeter of mercury (mm of Hg) Standard Deviation 13.240
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 32; n= 62, 67	-2.35 millimeter of mercury (mm of Hg) Standard Deviation 14.027	0.04 millimeter of mercury (mm of Hg) Standard Deviation 11.181
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 36; n= 62, 67	1.02 millimeter of mercury (mm of Hg) Standard Deviation 14.663	0.48 millimeter of mercury (mm of Hg) Standard Deviation 14.397
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 44; n= 61, 66	1.41 millimeter of mercury (mm of Hg) Standard Deviation 16.143	-0.36 millimeter of mercury (mm of Hg) Standard Deviation 13.694
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 48; n= 61, 65	-0.41 millimeter of mercury (mm of Hg) Standard Deviation 17.140	-0.22 millimeter of mercury (mm of Hg) Standard Deviation 12.351
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 56; n= 62, 63	0.06 millimeter of mercury (mm of Hg) Standard Deviation 15.216	1.02 millimeter of mercury (mm of Hg) Standard Deviation 13.559
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 60; n= 61, 65	0.61 millimeter of mercury (mm of Hg) Standard Deviation 15.627	-0.63 millimeter of mercury (mm of Hg) Standard Deviation 11.656
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels Absolute DBP; Baseline; n= 68, 68	80.21 millimeter of mercury (mm of Hg) Standard Deviation 10.127	76.22 millimeter of mercury (mm of Hg) Standard Deviation 9.646
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 4; n= 68, 68	-2.26 millimeter of mercury (mm of Hg) Standard Deviation 10.046	1.01 millimeter of mercury (mm of Hg) Standard Deviation 10.130
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 12; n= 66, 68	-1.92 millimeter of mercury (mm of Hg) Standard Deviation 10.115	-0.37 millimeter of mercury (mm of Hg) Standard Deviation 9.167
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 16; n= 64, 68	-1.36 millimeter of mercury (mm of Hg) Standard Deviation 10.237	0.46 millimeter of mercury (mm of Hg) Standard Deviation 9.824
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 20; n= 63, 68	-1.25 millimeter of mercury (mm of Hg) Standard Deviation 8.092	-1.19 millimeter of mercury (mm of Hg) Standard Deviation 9.214
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 36; n= 62, 67	-1.97 millimeter of mercury (mm of Hg) Standard Deviation 10.995	0.16 millimeter of mercury (mm of Hg) Standard Deviation 10.988
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 40; n= 62, 66	-0.48 millimeter of mercury (mm of Hg) Standard Deviation 9.625	-0.03 millimeter of mercury (mm of Hg) Standard Deviation 8.868
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 44; n= 61, 66	-0.79 millimeter of mercury (mm of Hg) Standard Deviation 9.930	-1.03 millimeter of mercury (mm of Hg) Standard Deviation 9.595
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 48; n= 61, 65	-3.26 millimeter of mercury (mm of Hg) Standard Deviation 10.466	-1.71 millimeter of mercury (mm of Hg) Standard Deviation 9.239
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 52; n= 61, 65	-3.66 millimeter of mercury (mm of Hg) Standard Deviation 10.628	-0.06 millimeter of mercury (mm of Hg) Standard Deviation 9.236
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 40; n= 62, 66	0.90 millimeter of mercury (mm of Hg) Standard Deviation 14.202	1.27 millimeter of mercury (mm of Hg) Standard Deviation 12.075
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP: Week 52; n= 61, 65	-1.03 millimeter of mercury (mm of Hg) Standard Deviation 13.200	-0.32 millimeter of mercury (mm of Hg) Standard Deviation 13.091
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 8; n= 67, 68	-2.04 millimeter of mercury (mm of Hg) Standard Deviation 8.461	-0.34 millimeter of mercury (mm of Hg) Standard Deviation 10.078
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 24; n= 63, 67	-2.24 millimeter of mercury (mm of Hg) Standard Deviation 8.751	-1.16 millimeter of mercury (mm of Hg) Standard Deviation 9.629
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 4; n= 68, 68	0.47 millimeter of mercury (mm of Hg) Standard Deviation 15.865	0.93 millimeter of mercury (mm of Hg) Standard Deviation 12.370
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 28; n= 63, 67	-2.02 millimeter of mercury (mm of Hg) Standard Deviation 9.939	0.36 millimeter of mercury (mm of Hg) Standard Deviation 10.071
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels SBP; Week 24; n= 63, 67	-1.54 millimeter of mercury (mm of Hg) Standard Deviation 15.449	-1.57 millimeter of mercury (mm of Hg) Standard Deviation 12.824
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 32; n= 62, 67	-4.27 millimeter of mercury (mm of Hg) Standard Deviation 9.313	-0.49 millimeter of mercury (mm of Hg) Standard Deviation 10.652
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 56; n= 62, 63	-3.48 millimeter of mercury (mm of Hg) Standard Deviation 10.570	0.11 millimeter of mercury (mm of Hg) Standard Deviation 8.899
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels DBP; Week 60; n= 61, 65	-2.54 millimeter of mercury (mm of Hg) Standard Deviation 11.278	-0.45 millimeter of mercury (mm of Hg) Standard Deviation 9.836

Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Pulse Rate Week 16; n= 64, 68	0.59 beats per minute (bpm) Standard Deviation 11.287	0.44 beats per minute (bpm) Standard Deviation 11.411
Change From Baseline in Pulse Rate Week 44; n= 61, 66	3.10 beats per minute (bpm) Standard Deviation 12.195	0.15 beats per minute (bpm) Standard Deviation 12.763
Change From Baseline in Pulse Rate Week 48; n= 61, 65	3.85 beats per minute (bpm) Standard Deviation 12.383	-1.12 beats per minute (bpm) Standard Deviation 10.315
Change From Baseline in Pulse Rate Week 52; n= 61, 65	1.85 beats per minute (bpm) Standard Deviation 11.987	-2.17 beats per minute (bpm) Standard Deviation 9.596
Change From Baseline in Pulse Rate Week 56; n= 62, 63	2.60 beats per minute (bpm) Standard Deviation 14.041	-0.35 beats per minute (bpm) Standard Deviation 9.986
Change From Baseline in Pulse Rate Week 60; n= 61, 65	1.51 beats per minute (bpm) Standard Deviation 12.793	0.09 beats per minute (bpm) Standard Deviation 10.280
Change From Baseline in Pulse Rate Absolute Baseline; n= 68, 68	77.38 beats per minute (bpm) Standard Deviation 13.763	75.75 beats per minute (bpm) Standard Deviation 10.404
Change From Baseline in Pulse Rate Week 4; n= 68, 68	2.01 beats per minute (bpm) Standard Deviation 12.294	1.87 beats per minute (bpm) Standard Deviation 10.543
Change From Baseline in Pulse Rate Week 8; n= 67, 68	0.97 beats per minute (bpm) Standard Deviation 10.718	-1.01 beats per minute (bpm) Standard Deviation 10.304
Change From Baseline in Pulse Rate Week 12; n= 66, 68	1.52 beats per minute (bpm) Standard Deviation 12.393	-0.12 beats per minute (bpm) Standard Deviation 10.855
Change From Baseline in Pulse Rate Week 20; n= 63, 68	1.03 beats per minute (bpm) Standard Deviation 11.521	-0.56 beats per minute (bpm) Standard Deviation 9.687
Change From Baseline in Pulse Rate Week 24; n= 63, 67	0.79 beats per minute (bpm) Standard Deviation 12.134	0.37 beats per minute (bpm) Standard Deviation 10.057
Change From Baseline in Pulse Rate Week 28; n= 62, 67	1.29 beats per minute (bpm) Standard Deviation 10.439	0.16 beats per minute (bpm) Standard Deviation 10.093
Change From Baseline in Pulse Rate Week 32; n= 62, 67	1.60 beats per minute (bpm) Standard Deviation 11.703	-0.31 beats per minute (bpm) Standard Deviation 10.530
Change From Baseline in Pulse Rate Week 36; n= 62, 67	3.47 beats per minute (bpm) Standard Deviation 12.538	-0.57 beats per minute (bpm) Standard Deviation 11.422
Change From Baseline in Pulse Rate Week 40; n= 62, 66	2.65 beats per minute (bpm) Standard Deviation 12.297	0.74 beats per minute (bpm) Standard Deviation 11.669

Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 24; n= 60, 66	2.8 milliseconds (msec) Standard Deviation 14.43	1.9 milliseconds (msec) Standard Deviation 16.66
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 60; n= 58, 63	1.2 milliseconds (msec) Standard Deviation 16.56	2.7 milliseconds (msec) Standard Deviation 17.27
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Any time post Baseline; n= 68, 68	18.8 milliseconds (msec) Standard Deviation 26.46	18.1 milliseconds (msec) Standard Deviation 15.28
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 8; n= 66, 66	0.1 milliseconds (msec) Standard Deviation 17.90	1.0 milliseconds (msec) Standard Deviation 15.03
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 16; n= 64, 66	0.8 milliseconds (msec) Standard Deviation 15.26	0.2 milliseconds (msec) Standard Deviation 14.05
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 32; n= 61, 66	6.2 milliseconds (msec) Standard Deviation 25.19	1.5 milliseconds (msec) Standard Deviation 17.16
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 40; n= 61, 65	-0.5 milliseconds (msec) Standard Deviation 15.25	-0.3 milliseconds (msec) Standard Deviation 17.53
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 52; n= 58, 64	2.0 milliseconds (msec) Standard Deviation 15.96	3.0 milliseconds (msec) Standard Deviation 16.04
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Week 60; n= 58, 63	3.0 milliseconds (msec) Standard Deviation 14.30	2.9 milliseconds (msec) Standard Deviation 14.97
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcF; Any time post Baseline; n= 68, 68	16.9 milliseconds (msec) Standard Deviation 23.74	15.4 milliseconds (msec) Standard Deviation 13.79
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 8; n= 66, 66	-0.8 milliseconds (msec) Standard Deviation 19.05	0.9 milliseconds (msec) Standard Deviation 17.31
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 16; n= 64, 66	-0.1 milliseconds (msec) Standard Deviation 18.33	-0.9 milliseconds (msec) Standard Deviation 14.76
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 24; n= 60, 66	1.4 milliseconds (msec) Standard Deviation 17.89	1.0 milliseconds (msec) Standard Deviation 18.10
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 32; n= 61, 66	5.2 milliseconds (msec) Standard Deviation 29.63	0.0 milliseconds (msec) Standard Deviation 19.63
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 40; n= 61, 65	-0.6 milliseconds (msec) Standard Deviation 17.83	-1.4 milliseconds (msec) Standard Deviation 18.88
Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values QTcB; Week 52; n= 58, 64	1.8 milliseconds (msec) Standard Deviation 17.64	0.7 milliseconds (msec) Standard Deviation 18.27

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk.phosph.; Week 8; n= 67, 66	-1.7 International Unit per Liter (IU/L) Standard Deviation 9.95	-1.7 International Unit per Liter (IU/L) Standard Deviation 11.56
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Absolute ALT; Baseline; n= 68, 68	19.9 International Unit per Liter (IU/L) Standard Deviation 8.91	21.3 International Unit per Liter (IU/L) Standard Deviation 14.22
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 4; n= 68, 68	0.2 International Unit per Liter (IU/L) Standard Deviation 6.17	-2.2 International Unit per Liter (IU/L) Standard Deviation 8.59
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 8; n= 67, 66	-0.9 International Unit per Liter (IU/L) Standard Deviation 5.66	-1.7 International Unit per Liter (IU/L) Standard Deviation 10.14
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 12; n= 65, 68	-0.9 International Unit per Liter (IU/L) Standard Deviation 4.53	-0.7 International Unit per Liter (IU/L) Standard Deviation 12.65
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 16; n= 65, 68	-0.4 International Unit per Liter (IU/L) Standard Deviation 6.56	-2.2 International Unit per Liter (IU/L) Standard Deviation 9.73
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 20; n= 63, 68	-0.3 International Unit per Liter (IU/L) Standard Deviation 6.25	-1.2 International Unit per Liter (IU/L) Standard Deviation 12.30
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 24; n= 63, 66	-1.3 International Unit per Liter (IU/L) Standard Deviation 5.38	-0.2 International Unit per Liter (IU/L) Standard Deviation 15.77
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 28; n= 62, 66	-0.9 International Unit per Liter (IU/L) Standard Deviation 6.73	-0.4 International Unit per Liter (IU/L) Standard Deviation 13.62
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 32; n= 61, 67	-0.7 International Unit per Liter (IU/L) Standard Deviation 6.79	-2.4 International Unit per Liter (IU/L) Standard Deviation 11.30
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 36; n= 60, 67	-0.1 International Unit per Liter (IU/L) Standard Deviation 6.21	-3.0 International Unit per Liter (IU/L) Standard Deviation 11.66
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 40; n= 61, 66	0.3 International Unit per Liter (IU/L) Standard Deviation 9.01	-2.3 International Unit per Liter (IU/L) Standard Deviation 11.70
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 44; n= 61, 66	0.9 International Unit per Liter (IU/L) Standard Deviation 9.68	-2.7 International Unit per Liter (IU/L) Standard Deviation 9.51
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 48; n= 61, 64	1.7 International Unit per Liter (IU/L) Standard Deviation 9.04	-1.6 International Unit per Liter (IU/L) Standard Deviation 15.47
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 52; n= 60, 65	1.5 International Unit per Liter (IU/L) Standard Deviation 10.42	-2.8 International Unit per Liter (IU/L) Standard Deviation 12.87
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 56; n= 61, 63	-0.1 International Unit per Liter (IU/L) Standard Deviation 7.35	-3.6 International Unit per Liter (IU/L) Standard Deviation 12.79
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels ALT; Week 60; n= 60, 65	-0.3 International Unit per Liter (IU/L) Standard Deviation 7.33	-4.7 International Unit per Liter (IU/L) Standard Deviation 14.11
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Absolute Alk.phosph.; Baseline; n= 68, 68	61.2 International Unit per Liter (IU/L) Standard Deviation 17.83	60.4 International Unit per Liter (IU/L) Standard Deviation 20.90
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk.phosph.; Week 4; n= 68, 68	-0.9 International Unit per Liter (IU/L) Standard Deviation 6.65	-3.2 International Unit per Liter (IU/L) Standard Deviation 10.01
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 12; n= 65, 68	-1.9 International Unit per Liter (IU/L) Standard Deviation 8.36	-1.1 International Unit per Liter (IU/L) Standard Deviation 12.99
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 16; n= 65, 68	-1.3 International Unit per Liter (IU/L) Standard Deviation 9.35	-1.1 International Unit per Liter (IU/L) Standard Deviation 14.61
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 20; n= 63, 68	0.0 International Unit per Liter (IU/L) Standard Deviation 11.24	4.4 International Unit per Liter (IU/L) Standard Deviation 21.90
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 24; n= 63, 66	-1.1 International Unit per Liter (IU/L) Standard Deviation 10.65	2.8 International Unit per Liter (IU/L) Standard Deviation 17.64
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 28; n= 62, 66	0.2 International Unit per Liter (IU/L) Standard Deviation 10.95	4.9 International Unit per Liter (IU/L) Standard Deviation 17.17
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 32; n= 61, 67	0.2 International Unit per Liter (IU/L) Standard Deviation 11.14	4.4 International Unit per Liter (IU/L) Standard Deviation 15.83
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 36; n= 60, 67	0.2 International Unit per Liter (IU/L) Standard Deviation 10.42	4.8 International Unit per Liter (IU/L) Standard Deviation 14.71
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 40; n= 61, 66	1.0 International Unit per Liter (IU/L) Standard Deviation 10.08	6.2 International Unit per Liter (IU/L) Standard Deviation 18.43
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 44; n= 61, 66	1.1 International Unit per Liter (IU/L) Standard Deviation 12.55	5.1 International Unit per Liter (IU/L) Standard Deviation 16.53
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 48; n= 61, 64	1.2 International Unit per Liter (IU/L) Standard Deviation 11.66	5.1 International Unit per Liter (IU/L) Standard Deviation 17.56
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 52; n= 60, 65	0.3 International Unit per Liter (IU/L) Standard Deviation 12.30	2.3 International Unit per Liter (IU/L) Standard Deviation 14.47
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 56; n= 61, 63	-0.9 International Unit per Liter (IU/L) Standard Deviation 12.04	1.7 International Unit per Liter (IU/L) Standard Deviation 16.42
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Alk. phosph.; Week 60; n= 60, 65	-1.5 International Unit per Liter (IU/L) Standard Deviation 13.16	1.0 International Unit per Liter (IU/L) Standard Deviation 15.08
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels Absolute AST; Baseline; n= 68, 68	19.3 International Unit per Liter (IU/L) Standard Deviation 6.11	21.8 International Unit per Liter (IU/L) Standard Deviation 10.73
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 4; n= 68, 68	0.0 International Unit per Liter (IU/L) Standard Deviation 4.41	-1.7 International Unit per Liter (IU/L) Standard Deviation 8.61
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 8; n= 67, 66	-0.4 International Unit per Liter (IU/L) Standard Deviation 4.77	-1.0 International Unit per Liter (IU/L) Standard Deviation 8.21
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 12; n= 65, 68	0.5 International Unit per Liter (IU/L) Standard Deviation 4.41	-0.7 International Unit per Liter (IU/L) Standard Deviation 9.62
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 16; n= 65, 68	0.4 International Unit per Liter (IU/L) Standard Deviation 5.48	-0.6 International Unit per Liter (IU/L) Standard Deviation 7.90
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 20; n= 63, 68	0.8 International Unit per Liter (IU/L) Standard Deviation 4.66	-0.6 International Unit per Liter (IU/L) Standard Deviation 8.49
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 24; n= 63, 66	0.0 International Unit per Liter (IU/L) Standard Deviation 4.46	-0.4 International Unit per Liter (IU/L) Standard Deviation 10.44
Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels AST; Week 28; n= 61, 66	-0.9 International Unit per Liter (IU/L) Standard Deviation 5.34	-0.4 International Unit per Liter (IU/L) Standard Deviation 10.59

Outcome measures
Measure	Placebo n=68 Participants Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	Mepolizumab 300mg n=68 Participants Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 8; n= 1, 0	-0.350 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.	—
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 12; n= 1, 0	0.190 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.	—
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 16; n= 1, 1	-0.730 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.	-0.790 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 20; n= 1, 1	-0.150 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.	-0.540 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 24; n= 0, 1	—	0.040 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 36; n= 0, 1	—	0.250 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 52; n= 58, 64	0.016 millimoles per liter (mmol/L) Standard Deviation 0.7717	-0.215 millimoles per liter (mmol/L) Standard Deviation 0.8079
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels LDL cholesterol; Week 56; n= 1, 0	0.100 millimoles per liter (mmol/L) Standard Deviation NA NA indicates that data was not available.	—
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Absolute Phosphate; Baseline; n= 68, 68	1.068 millimoles per liter (mmol/L) Standard Deviation 0.1797	1.066 millimoles per liter (mmol/L) Standard Deviation 0.1939
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 4; n= 68, 68	-0.027 millimoles per liter (mmol/L) Standard Deviation 0.2183	0.014 millimoles per liter (mmol/L) Standard Deviation 0.1833
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 8; n= 67, 66	-0.004 millimoles per liter (mmol/L) Standard Deviation 0.1577	0.024 millimoles per liter (mmol/L) Standard Deviation 0.2239
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 12; n= 65, 68	0.003 millimoles per liter (mmol/L) Standard Deviation 0.1821	0.019 millimoles per liter (mmol/L) Standard Deviation 0.2181
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 16; n= 65, 68	0.016 millimoles per liter (mmol/L) Standard Deviation 0.1819	0.016 millimoles per liter (mmol/L) Standard Deviation 0.2205
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 20; n= 63, 68	-0.001 millimoles per liter (mmol/L) Standard Deviation 0.1611	0.019 millimoles per liter (mmol/L) Standard Deviation 0.2087
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 24; n= 63, 66	-0.042 millimoles per liter (mmol/L) Standard Deviation 0.1565	0.007 millimoles per liter (mmol/L) Standard Deviation 0.2142
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 28; n= 62, 66	-0.025 millimoles per liter (mmol/L) Standard Deviation 0.1819	0.003 millimoles per liter (mmol/L) Standard Deviation 0.2539
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 32; n= 61, 67	-0.018 millimoles per liter (mmol/L) Standard Deviation 0.1975	0.040 millimoles per liter (mmol/L) Standard Deviation 0.2172
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 36; n= 60, 67	-0.038 millimoles per liter (mmol/L) Standard Deviation 0.2159	0.023 millimoles per liter (mmol/L) Standard Deviation 0.2260
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 40; n= 61, 66	-0.029 millimoles per liter (mmol/L) Standard Deviation 0.1822	0.026 millimoles per liter (mmol/L) Standard Deviation 0.2213
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 44; n= 61, 66	-0.018 millimoles per liter (mmol/L) Standard Deviation 0.2104	0.041 millimoles per liter (mmol/L) Standard Deviation 0.2240
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 48; n= 61, 64	-0.053 millimoles per liter (mmol/L) Standard Deviation 0.1931	-0.020 millimoles per liter (mmol/L) Standard Deviation 0.2443
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 52; n= 60, 65	0.005 millimoles per liter (mmol/L) Standard Deviation 0.1939	0.053 millimoles per liter (mmol/L) Standard Deviation 0.2988
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 56; n= 61, 63	0.019 millimoles per liter (mmol/L) Standard Deviation 0.2962	0.043 millimoles per liter (mmol/L) Standard Deviation 0.3066
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Phosphate; Week 60; n= 60, 65	-0.035 millimoles per liter (mmol/L) Standard Deviation 0.2125	-0.007 millimoles per liter (mmol/L) Standard Deviation 0.2322
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Absolute Potassium; Baseline; n= 68, 68	4.11 millimoles per liter (mmol/L) Standard Deviation 0.348	4.10 millimoles per liter (mmol/L) Standard Deviation 0.359
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 4; n= 68, 68	0.05 millimoles per liter (mmol/L) Standard Deviation 0.378	-0.02 millimoles per liter (mmol/L) Standard Deviation 0.345
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 8; n= 67, 66	0.01 millimoles per liter (mmol/L) Standard Deviation 0.309	0.02 millimoles per liter (mmol/L) Standard Deviation 0.323
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 12; n= 65, 68	-0.04 millimoles per liter (mmol/L) Standard Deviation 0.318	0.01 millimoles per liter (mmol/L) Standard Deviation 0.296
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 16; n= 65, 68	0.06 millimoles per liter (mmol/L) Standard Deviation 0.340	0.05 millimoles per liter (mmol/L) Standard Deviation 0.317
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 20; n= 63, 68	0.08 millimoles per liter (mmol/L) Standard Deviation 0.382	0.01 millimoles per liter (mmol/L) Standard Deviation 0.372
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Sodium; Week 4; n= 68, 68	0.2 millimoles per liter (mmol/L) Standard Deviation 1.86	0.3 millimoles per liter (mmol/L) Standard Deviation 2.03
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 24; n= 63, 66	-0.02 millimoles per liter (mmol/L) Standard Deviation 0.298	0.04 millimoles per liter (mmol/L) Standard Deviation 0.350
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 28; n= 61, 66	0.07 millimoles per liter (mmol/L) Standard Deviation 0.338	0.10 millimoles per liter (mmol/L) Standard Deviation 0.382
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 32; n= 61, 67	0.04 millimoles per liter (mmol/L) Standard Deviation 0.340	0.11 millimoles per liter (mmol/L) Standard Deviation 0.305
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 36; n= 60, 67	0.02 millimoles per liter (mmol/L) Standard Deviation 0.291	0.01 millimoles per liter (mmol/L) Standard Deviation 0.351
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 40; n= 61, 66	0.08 millimoles per liter (mmol/L) Standard Deviation 0.419	0.14 millimoles per liter (mmol/L) Standard Deviation 0.313
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 44; n= 61, 66	0.08 millimoles per liter (mmol/L) Standard Deviation 0.383	0.09 millimoles per liter (mmol/L) Standard Deviation 0.341
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 48; n= 61, 64	0.09 millimoles per liter (mmol/L) Standard Deviation 0.367	0.05 millimoles per liter (mmol/L) Standard Deviation 0.349
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 52; n= 60, 65	0.05 millimoles per liter (mmol/L) Standard Deviation 0.344	0.01 millimoles per liter (mmol/L) Standard Deviation 0.329
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels Potassium; Week 56; n= 61, 63	0.08 millimoles per liter (mmol/L) Standard Deviation 0.379	0.08 millimoles per liter (mmol/L) Standard Deviation 0.378